Brilakis, L;
Theofilogiannakou, E;
Lykoudis, PM;
(2024)
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19.
World Journal of Gastroenterology
, 30
(11)
pp. 1480-1487.
10.3748/wjg.v30.i11.1480.
Preview |
PDF
07. Brilakis-2024-Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19.pdf - Published Version Download (1MB) | Preview |
Abstract
During the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleukin 6, which appeared particularly elevated in those patients and was deemed responsible for additional insult to the already damaged liver. This should increase our vigilance in terms of early detection, close follow up and early treatment for individuals with MAFLD and COVID-19 infection. In the direction of early diagnosis, biomarkers such as cytokeratin-18 and scoring systems such as Fibrosis-4 index score are proposed. COVID-19 is a newly described entity, expected to be of concern for the years to come, and MAFLD is a condition with an ever-increasing impact. Delineating the interaction between these two entities should be brought into the focus of research. Reducing morbidity and mortality of patients with COVID-19 and MAFLD should be the ultimate objective, and the optimal way to achieve this is by designing evidence-based prevention and treatment policies.
| Type: | Article |
|---|---|
| Title: | Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3748/wjg.v30.i11.1480 |
| Publisher version: | http://dx.doi.org/10.3748/wjg.v30.i11.1480 |
| Language: | English |
| Additional information: | This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Keywords: | Metabolic dysfunction-associated fatty liver disease; COVID-19; Liver fibrosis; Cytokine storm; Drug induced liver injury |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10190954 |
Archive Staff Only
 |
View Item |
